In a nutshell This study reported the final effectiveness and safety outcomes of neratinib treatment in patients with early-stage HER2+/HR+ breast cancer. The data showed that neratinib significantly improved invasive disease-free survival in these patients who initiated treatment within 1 year of trastuzumab-based therapy. Some background...Read More
Type(s) of biological therapy-Trastuzumab (Herceptin) Posts on Medivizor
Is heart monitoring needed in patients with HER2-positive metastatic breast cancer using trastuzumab?
In a nutshell This article looked at the occurrence of heart-related side effects in patients with HER2-positive metastatic breast cancer (mBC) receiving trastuzumab (Herceptin). The authors found that non-smoking patients with a good heart function before receiving treatment have a low risk of heart toxicity (HT) after 4 years...Read More
In a nutshell This study investigated if a combination including pertuzumab (Perjeta) and subcutaneous trastuzumab (Herceptin Hylecta) is safe in breast cancer (BC). They found that this combination was well tolerated in patients with HER2-positive BC. Some background Breast cancer (BC) is the most common cancer in...Read More
Lisinopril versus carvedilol to prevent trastuzumab-related heart problems in patients with breast cancer.
In a nutshell This study wanted to find out if lisinopril (Zestril) or carvedilol (Coreg) can help prevent heart problems in patients with HER2 positive breast cancer who are treated with trastuzumab (Herceptin). The study found that both of these medications helped reduce the chance of heart problems in these patients if they were also being...Read More
In a nutshell This study wanted to find out which medication is better for treating HER-2 positive breast cancer, a class of medicines called anthracyclines plus trastuzmab (Herceptin) and pertuzmab (Perjeta), or carboplatin (Paraplatin) plus trastuzmab and pertuzmab. The study found that both medications worked equally as well as each other, but the...Read More
Addition of traustuzumab to adjuvant anthracycline and taxane based chemotherapy does not worsen long-term heart function or health related quality of life.
In a nutshell This study set out to evaluate heart function in patients who received traustuzumab with anthracycline and taxane–based chemotherapy. This study concluded that, in patients without heart disease at baseline, adding traustuzumab to adjuvant anthracycline and taxane–based...Read More
Video information: Breast cancer experts gathered at the 2017 American Society of Clinical Oncology meeting to discuss developments in research and treatment. Patient Power founder, Andrew Schorr, was on-site in Chicago and interviewed Dr. Julie Gralow, Director of Breast Medical Oncology at the Seattle Cancer Care Alliance. Dr. Gralow shares...Read More
The effectiveness and cardiac safety of CMF plus trastuzumab in HER2-positive metastatic breast cancer
In a nutshell This study investigated the safety and effectiveness of treatment with combination cyclophosphamide (Cytoxan), methotrexate (Otrexup) and 5-fluoruoracil (Efudex) (CMF) plus trastuzumab (Herceptin) in HER2-positive metastatic breast cancer (MBC, cancer that has spread beyond the breast) patients. CMF plus trastuzumab (CMF+T) was found to...Read More
How does hormone receptor status affect patient response to trastuzumab therapy in metastatic breast cancer
In a nutshell This study investigated the clinical factors that influence patient response to trastuzumab (Herceptin) therapy in human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer (MBC). Hormone receptor (HR) status was found to be a possible predictor of a strong response to trastuzumab-based therapy. Some background...Read More
In a nutshell This study investigated the role of trastuzumab (Herceptin) as part of standard care in patients with human epidermal growth factor receptor-2 positive (HER2+) early breast cancer (BC). The study conclude that trastuzumab was effective in general practice, including patients not often included in clinical trials (such as the...Read More
In a nutshell This study investigated the rate and outcome of trastuzumab (Herceptin) associated cardiac (heart) dysfunction in patients after 1 or 2 years of therapy. The study concluded that for patients treated with adjuvant trastuzamab, the occurrence of cardiac events remained low and that these cardiac events were mostly reversible after...Read More
In a nutshell The authors aimed to determine whether or not the breast cancer treatment trastuzumab (Herceptin) increased the risk of developing certain infections. Some background Human epidermal growth factor receptor positive (HER2+) breast cancers are dependent on the HER2 protein for growth. It is often targeted with a particular...Read More